As a 34‑year‑old with suspected von Willebrand disease and a failing 12‑year‑old porcine bioprosthetic valve, should I obtain definitive von Willebrand testing before deciding between a valve‑in‑valve transcatheter replacement or open‑heart surgery with a mechanical valve, and what factors should guide this choice?

Yes, obtain definitive von Willebrand disease testing before your valve replacement surgery—your suspected bleeding disorder fundamentally changes which valve type you should receive and may alter your surgical approach.

Given your age (34), family history, prior excessive bleeding during cardiac surgery, and need for valve replacement, you should NOT receive a mechanical valve if von Willebrand disease is confirmed, as the mandatory lifelong anticoagulation with warfarin would dramatically increase your bleeding risk and potentially be life-threatening.

Why VWD Testing Must Come First

Your clinical picture strongly suggests von Willebrand disease:

• Positive family history (grandfather confirmed VWD)
• Documented excessive bleeding during your first heart surgery
• Age 34 with recurrent need for intervention

The 2025 diagnostic guidelines emphasize that no single test diagnoses VWD 1. You need a comprehensive panel including:

• VWF antigen (VWF:Ag) - measures total protein
• VWF activity assay - preferably VWF:GPIbM or VWF:GPIbR (NOT the older ristocetin cofactor assay which has poor reproducibility and can give false results)
• Factor VIII level
• VWF multimer analysis if initial tests are abnormal

Critical pitfall: Your previous negative test may have been falsely negative due to:

• Testing during acute stress/surgery (VWF rises with stress, masking the deficiency)
• Use of older, less sensitive assays
• Incomplete testing panel
• Blood type O individuals naturally have 25-30% lower VWF levels, complicating diagnosis 1

Valve Choice Algorithm Based on VWD Status

If VWD is CONFIRMED:

You must receive another bioprosthetic valve—mechanical valves are contraindicated 2.

Here's why this is non-negotiable:

• Mechanical valves require lifelong warfarin anticoagulation to prevent valve thrombosis
• Anticoagulation with warfarin in a patient with VWD creates a catastrophic bleeding risk
• The 2020 ACC/AHA guidelines explicitly state: "If anticoagulation is contraindicated or if the patient refuses VKA therapy, an alternative valve choice is appropriate" 2
• Your bleeding disorder makes anticoagulation contraindicated

Your options with confirmed VWD:

1. Valve-in-valve TAVR (transcatheter valve inside your old bioprosthetic valve)

   • Less invasive
   • Lower bleeding risk during procedure
   • Faster recovery
   • Appropriate for your anatomy if the old valve frame is suitable

2. Open surgical bioprosthetic valve replacement

   • Allows complete removal of deteriorated valve
   • May provide better hemodynamics
   • Higher perioperative bleeding risk BUT manageable with VWF replacement therapy

Perioperative bleeding management with confirmed VWD:

• You will need VWF/Factor VIII concentrate replacement therapy perioperatively 3
• Target VWF activity and Factor VIII levels >50% for major surgery 4
• Desmopressin (DDAVP) is insufficient for major cardiac surgery—you need VWF concentrates 3
• Important finding: Research shows that acquired VWD from aortic valve disease often corrects during cardiopulmonary bypass 5, but your hereditary VWD will NOT correct and requires treatment

If VWD is EXCLUDED:

At age 34, ACC/AHA guidelines favor a mechanical valve 2.

The evidence is clear:

• Patients <50 years have a 30% risk of needing reoperation at 15 years with a bioprosthetic valve (your pig valve lasted 12 years, consistent with this data)
• At age 34, you face a 50% chance of needing another reoperation if you get another bioprosthetic valve 2
• "The balance between valve durability and risk of bleeding and thromboembolic events favors the choice of a mechanical valve in patients <50 years of age" 2
• Anticoagulation with warfarin can be accomplished with acceptable risk in compliant patients with appropriate INR monitoring 2

However, if you strongly prefer to avoid lifelong anticoagulation even without VWD:

• Another bioprosthetic valve is reasonable but understand you're likely facing a third operation in your 40s
• Valve-in-valve TAVR may be an option for your next failure, but durability data beyond 5-6 years is lacking 2

Practical Next Steps

1. Before your CT and right heart catheterization next week, request VWD testing:

   • 4-test panel: Factor VIII, VWF:Ag, VWF:GPIbM or VWF:GPIbR, VWF collagen binding
   • Must be done when you're NOT acutely ill or stressed
   • Avoid testing during menstruation if applicable
   • Consider genetic testing of VWF gene given strong family history 6

2. Coordinate with hematology: You need a hematologist involved in your surgical planning if VWD is confirmed

3. Surgical approach decision:

   • If VWD confirmed → Bioprosthetic valve (surgical vs valve-in-valve based on anatomy and surgeon expertise)
   • If VWD excluded → Mechanical valve is the evidence-based choice at your age, unless you have strong personal preference against anticoagulation

Critical Caveat About Your Exhaustion

Your severe fatigue may indicate:

• Worsening heart failure from valve dysfunction
• Anemia from chronic bleeding (common in VWD)
• Both factors need urgent evaluation

Your exhaustion actually argues for proceeding with intervention sooner rather than later—but the 1-2 weeks needed for proper VWD testing will not significantly delay your surgery and is essential for choosing the right valve and planning perioperative hemostatic management.

The bottom line: Definitive VWD testing is not optional—it determines whether you can safely receive a mechanical valve (which would otherwise be the best choice at your age) or must receive another bioprosthetic valve despite the high likelihood of needing a third operation.